A paradigmatic illustration of SL‐mediated targeted therapy resides in the DNA damage repair pathway: inhibitors of poly (ADP‐ribose) polymerase (PARP), encoded by PARP1, exploit SL to selectively eliminate cancer cells harbouring deficiencies in BRCA1 or BRCA2.2 The gene discussed is BRCA2; the disease is cancer.